Antitumor agent-105
Antitumor agent-105 (Compound 37) is an antitumor agent. Antitumor agent-105 has antitumor activity against A549, H1299, H460, HCT116, MDA-MB-231 cells, with IC50 values of 6.7, 8.3, 4.3, 4.4, 6.7 μM respectively.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C26H30N2O4
- Masse moléculaire:434.53
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
6.7 μM
Compound: 37
|
Antitumor activity against human A549 cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human A549 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
| HCT-116 | IC50 |
4.4 μM
Compound: 37
|
Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human HCT-116 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
| Hep 3B2 | IC50 |
>10 μM
Compound: 37
|
Antitumor activity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human Hep3B cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
| MDA-MB-231 | IC50 |
6.7 μM
Compound: 37
|
Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human MDA-MB-231 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
| NCI-H1299 | IC50 |
8.3 μM
Compound: 37
|
Antitumor activity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human NCI-H1299 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
| NCI-H460 | IC50 |
4.3 μM
Compound: 37
|
Antitumor activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay
Antitumor activity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay
|
[PMID: 37271378] |
Chemical Information
-
Masse moléculaire 434.53
-
Formule C26H30N2O4
-
SMILES
[H][C@]([C@@]1([H])O2)(COC3=C1C=C4C(OC(C)(C)C=C4)=C3)C5=C2C=C(C=C5)OCCN6CCNCC6
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antitumor agent-105 Related Classifications
HY-155039 Related Classifications
Powered by Bioz